Calidi Biotherapeutics CEO: How RedTail Could Transform Cancer Treatment | CLDI Interview
Dec. 2, 2025
In our exclusive interview, Calidi Biotherapeutics (NYSE American: CLDI) CEO Eric Poma, PhD, breaks down how the company’s RedTail platform is designed to overcome one of oncology’s biggest challenges: delivering potent genetic medicines systemically to metastatic tumors.
Calidi is advancing a next generation enveloped vaccinia virus engineered to evade immune clearance and directly target tumor sites across multiple aggressive cancers including NSCLC, triple negative breast cancer, ovarian cancer, melanoma, soft tissue sarcoma, and glioblastoma.
Dr. Poma discusses:
• How RedTail avoids rapid immune elimination, enabling true systemic delivery
• Preclinical success of lead candidate CLD 401, including tumor regression in stringent immune-competent models
• The IL15 superagonist payload designed to amplify anti-tumor immune responses
• Manufacturing scalability, with cost of goods comparable to monoclonal antibodies
• Clinical roadmap, with IND filing targeted by the end of next year and early clinical readouts expected soon after
• The value proposition for investors, as RedTail represents a potential new therapeutic modality with multibillion-dollar market relevance
• A large addressable market, with systemic tumor-targeting genetic medicines addressing an estimated 13B–15B dollars annually in the US
???? Calidi Biotherapeutics is a client of RedChip. To learn more about CLDI and to read our full disclosure, visit: CLDIinfo.com.
